Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ET 019002

Drug Profile

ET 019002

Alternative Names: ET019002-T Cell Therapy; ET019002-T Cells

Latest Information Update: 28 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eureka Therapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 24 Aug 2018 Eureka Therapeutics and First Affiliated Hospital Xi'an Jiaotong University plans a phase I trial for Precursor cell lymphoblastic leukaemia-lymphoma and B-cell lymphoma (In children, In adolescents, In adults, In the elderly, Second-line therapy or greater) in August 2018 (NCT03642496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top